A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

Primary Study Inclusion Criteria:

• Documented estrogen receptor (ER)-positive and HER2-negative breast tumor, asassessed locally on a primary disease specimen

• Participants who have multicentric (the presence of two of more tumor foci withindifferent quadrants of the same breast) and/or multifocal (the presence of two ormore tumor foci within a single quadrant of the breast) breast cancer are alsoeligible if all examined tumors meet pathologic criteria for ER positivity and HER2negativity

• Participants must have undergone definitive surgery of their primary breast tumor(s)and axillary lymph nodes (axillary lymph node dissection [ALND] and/or sentinellymph node biopsy [SLNB])

• Participants who received or will be receiving adjuvant chemotherapy must havecompleted adjuvant chemotherapy prior to randomization. Participants may also havereceived neoadjuvant chemotherapy. A washout period of at least 21 days is requiredbetween last adjuvant chemotherapy dose and randomization.

• Resolution of all acute toxic effects of prior anti-cancer therapy or surgicalprocedures to NCI CTCAE v5.0 Grade 1 or better (except alopecia, Grade ≤2 peripheralneuropathy, arthralgia or other toxicities not considered a safety risk for theparticipant per the investigator's judgment)

• Participants have received (neo)adjuvant chemotherapy and/or had surgery and had noprior endocrine therapy are eligible, provided that they are enrolled within 12months following definitive breast cancer surgery

• Participants who have confirmed availability of an untreated primary breast tumortissue specimen suitable for biomarker testing (i.e., representative archivedformalin-fixed, paraffin-embedded [FFPE] tissue block [preferred] or 15-20 slidescontaining unstained, freshly cut, serial sections), with associated de-identifiedpathology report is required. Although 15-20 slides are preferred, if only 10-14slides are available, the individual may still be eligible for the study.

• Participants with node-positive and node-negative disease are eligible provided theymeet additional risk criteria as defined in the protocol

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1, or 2

• Able and willing to swallow, retain, and absorb oral medication

• Adequate organ function

Substudy Inclusion Criteria:

To be eligible for substudy participation, in addition to meeting the inclusion criteria in the primary protocol, participants must also meet the following modified criteria:

• Patients who received adjuvant radiotherapy must have completed radiotherapy prior to enrollment, and patients must have recovered (to Grade ≤1) from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and enrollment.

Primary Study Exclusion Criteria:

• Pregnant or breastfeeding, or intending to become pregnant during the study orwithin 10 days after the final dose of giredestrant, or within the time periodspecified per local prescribing guidelines after the final dose of the endocrinetherapy of physician's choice

• Received treatment with investigational therapy within 28 days prior to initiationof study treatment or is currently enrolled in any other type of medical researchjudged by the sponsor not to be scientifically or medically compatible with thisstudy

• Receiving or planning to receive a CDK4/6 inhibitor as (neo)adjuvant therapy. Ashort course of up to 12 weeks of neoadjuvant or adjuvant treatment with CDK4/6inhibitor therapy prior to randomization is allowed.

• Active cardiac disease or history of cardiac dysfunction

• Diagnosed with Stage IV breast cancer

• A history of any prior (ipsilateral and/or contralateral) invasive breast cancer orductal carcinoma in situ (DCIS). Participants with a history of contralateral DCIStreated by only local regional therapy at any time may be eligible.

• A history of any other malignancy within 3 years prior to screening, except forappropriately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma,or Stage I uterine cancer

• Any prior endocrine treatment with selective ER modulators (e.g., tamoxifen),degraders, or aromatase inhibitors. A short course of neoadjuvant or adjuvantendocrine therapy (up to 12 weeks) is allowed.

• Clinically significant liver disease consistent with Child-Pugh Class B or C,including active hepatitis (e.g., hepatitis B virus [HBV] or hepatitis C virus [HCV]), current alcohol abuse, cirrhosis, or positive test for viral hepatitis

• Treatment with strong CYP3A4 inhibitors or inducers within 14 days or 5 drugelimination half-lives (whichever is longer) prior to initiation of study treatment

• Known allergy or hypersensitivity to any of the study drugs or any of theirexcipients

• Pre- and perimenopausal participants or male participants who have a knownhypersensitivity to LHRH agonists

• A documented history of hemorrhagic diathesis, coagulopathy, or thromboembolism

• Renal dysfunction that requires dialysis

• A major surgical procedure unrelated to breast cancer within 28 days prior torandomization

• A serious infection requiring oral or IV antibiotics within 14 days prior toscreening or other clinically significant infection (e.g., COVID-19) within 14 daysprior to screening

• Any serious medical condition or abnormality in clinical laboratory tests that, inthe investigator's judgment, precludes an individual's safe participation in andcompletion of the study

• Unable or unwilling to comply with the requirements of the protocol in the opinionof the investigator

Substudy Exclusion Criteria:

Potential participants are excluded from the substudy if any criteria from t\he primary study or the following criteria apply:

• Prior participation in the GO42784 primary study

• Received a CDK4/6i as (neo)adjuvant therapy prior to enrollment

• Treatment with moderate CYP3A inducers, strong CYP3A inducers or strong CYP3Ainhibitors within 14 days or 5 drug elimination half-lives (whichever is longer)prior to initiation of study treatment